Pancreatic cancer is one of the deadliest forms of cancer. So any bit of progress on the pancreatic cancer front is a big deal. And researchers are happy to report they've found a chemotherapy drug that can help patients who have received surgery prevent a return of the disease for a longer period of time.

In a German study, participants who received Gemzar, or gemcitabine, lived an average of 13.4 months without their cancers coming back. Participants who did not receive the drug lived without the disease for 6.9 months. While the findings of this study may seem modest, they really are quite encouraging because pancreatic cancer is such a rapid killer, and patients with this disease have the worst chances of recovery.

This study, published in Wednesday's Journal of the American Medical Association, brings hope for the mere 20 percent of pancreatic cancer patients who are candidates for surgery. While surgery is the best hope for a cure, the disease still returns in the majority of cases -- so Gemzar is surely worth a shot.

It should be noted that some study authors report financial ties to Gemzar drugmaker Eli Lilly and Co. Researchers, however, report the firm had no influence in design or data interpretation.

Pancreatic cancer is considered one of the most deadly of cancers. The statistics are grim, as 95 percent of patients diagnosed with pancreatic cancer do not survive, and 50 percent of patients die within six months after the cancer is diagnosed. There might be some hope in an allergy medication that has been around for 40 years.

According to University of Texas M. D. Anderson Cancer Center researchers, the allergy medication cromolyn reduced pancreatic tumor growth in mouse model studies, and when the drug was combined with the chemotherapy drug gemcitabine, the standard chemotherapy treatment was three times more effective. They are reported to be in the process of starting a clinical trial.

The study's lead author, Craig Logsdon, Ph.D. is quoted as saying, "The study demonstrates in mouse models of human pancreatic cancer that the cromolyn-gemcitabine combination reduced cancer growth by 85 percent compared to control animals. Cromolyn used alone actually had a good effect on reduction of tumors compared to control animals, which surprised us. It reduced tumor growth by 70 percent, compared to growth reduction of 50 percent when gemcitabine was used as a single agent."

"Our goal is to offer longer life to these patients, and the combination of these two agents may well do that."

To learn more about pancreatic cancer, visit the pancreatic cancer category here and the National Cancer Institute's What You Need To Know About Cancer of the Pancreas.

Postmenopausal women with HER2 positive breast cancer that also have hormone receptor positive disease can benefit significantly when treatment involves adding Herceptin to the drug Arimidex. Combining these two drugs can lengthen the time women with advanced breast cancer live without their disease progressing.

The full findings were released on Monday at the European Society for Medical Oncology Congress in Istanbul. Roche Pharmaceuticals had announced back in May that Herceptin plus Arimidex combination had produced good results.

"The results are very positive" said Dr. Bella Kaufman of Israel's Chaim Sheba Medical Center who led the research. "In breast cancer, there are not many trials that show double progression-free survival."

Bubbling from the earth in Balmoral, Scotland is a mineral water that appears to slow the growth of cancerous cells -- so say scientists who tested the mineral water against tap water. In laboratory testing, the mineral water slowed colon cancer cells 62 percent better than tap water; slowed liver cancer by 35 percent, and slowed cervical cancer by 21 percent better than tap water.

Deeside Mineral Water first came to be known as offering health benefit in 1760, when a local woman is reported to have been cured of Scrofula by drinking and bathing in the Balmoral waters. Back then, the waters were thought of as an agent in miraculous effect. Lord Byron, Sir Walter Scott and Queen Victoria are said to have been attracted to the area for this reason.

A Deeside Mineral Water spokesman is adamant in insisting that they do not believe that the bottled water holds out any promise of a miracle cure -- only that it might be considered a complementary therapy in conjunction with conventional medical treatments. We are certainly glad they made that clear.

From our understanding of the online literature published by the Deeside Mineral Water company, the bottled water needs to be consumed on a daily basis for a number of weeks to show benefit, and one would have to continue drinking the bottled water to maintain health benefits the mineral water is reported to offer. For more information, visit the Deeside Mineral Water website.

According to previous research, pomegranate juice shrank prostate cancer cells in lab dishes and in mice. Researchers found that prostate tumors shrank in mice infected with human prostate tumors, who were given pomegranate juice to drink. New research indicates that pomegranate juice has such a significant effect in slowing the growth of prostate tumors that older men, aged 65 and above, might actually outlive prostate cancer, rather than dying from it.

In order for pomegranate juice to offer protective benefit in slowing down prostate tumor growth, men need to drink an eight-ounce glass of the juice daily. The results of this study are so encouraging it leads researchers to believe that drinking pomegranate juice might be a viable alternative to other therapies such as hormone treatment or chemotherapy. If you are an older man diagnosed with prostate cancer, the results of this study are certainly worth discussing with your physician.